Our website uses cookies. By clicking on accept, you give your consent to the use of cookies as per our Privacy Policy.
01 Dec, 2023
Acute Lymphoblastic Leukemia (ALL), a cancer that affects the blood and bone marrow, is a challenging condition to treat. However, recent advancements in medical research have led to the development of targeted therapies that offer new hope to patients diagnosed with ALL. In this blog post, we will delve into the promising approaches in the field of targeted therapies for ALL, exploring how these treatments work and their potential benefits for patients.
Find the right cosmetic procedure for your needs.
We specialize in a wide range of cosmetic procedures
Before we dive into the promising therapies, it's essential to understand what ALL is. ALL is a type of leukemia that primarily affects lymphocytes, a type of white blood cell. In ALL, abnormal lymphoblasts (immature white blood cells) multiply rapidly, crowding out healthy blood cells. Traditional treatments for ALL have included chemotherapy, radiation, and stem cell transplantation. However, these treatments can be harsh and often come with significant side effects.
Tyrosine kinases are enzymes that play a critical role in cell signaling and growth. When these enzymes become mutated or overactive, they can drive uncontrolled cell division, contributing to cancer development. In the context of ALL, specific mutations are present in a subset of patients known as Philadelphia chromosome-positive (Ph+) ALL. In these cases, tyrosine kinase inhibitors (TKIs) have emerged as promising treatments.
Dasatinib: Similar to imatinib, dasatinib is a TKI that targets BCR-ABL, but it is designed to be effective against specific resistance mutations that may develop during imatinib treatment. This provides an alternative treatment option for patients who may become resistant to imatinib.
Monoclonal antibodies are synthetic proteins designed to target specific markers on cancer cells, marking them for destruction by the immune system. In the context of ALL, blinatumomab is a significant breakthrough:
Blinatumomab: Blinatumomab is a bispecific T-cell engager (BiTE) antibody that binds to CD19, a protein commonly found on the surface of B-cell ALL. It has shown remarkable success in treating relapsed or refractory B-cell ALL. Blinatumomab brings T-cells in close proximity to leukemia cells, stimulating an immune response that leads to the destruction of cancer cells. This approach has shown substantial efficacy and is well-tolerated by many patients.
CAR T-cell therapy is a groundbreaking and highly personalized approach to treating ALL. It involves modifying a patient's own T-cells to express a receptor that targets leukemia cells. Two prominent CAR T-cell therapies for ALL are:
Tisagenlecleucel (Kymriah) and Axicabtagene Ciloleucel (Yescarta): Both of these CAR T-cell therapies are engineered to recognize and bind to the CD19 antigen on the surface of B-cell ALL cells. After infusion into the patient, these modified T-cells proliferate and specifically target and eliminate cancerous cells expressing CD19. CAR T-cell therapy has achieved remarkable responses in patients with relapsed or refractory ALL, often providing a potential cure for those who had limited treatment options.
Small molecule inhibitors are drugs that target specific proteins or pathways within leukemia cells. In the case of venetoclax:
Venetoclax: Venetoclax inhibits the BCL-2 protein, which is involved in blocking apoptosis (programmed cell death) in leukemia cells. By blocking BCL-2, venetoclax promotes apoptosis in ALL cells, leading to their death. This drug has shown promise in treating certain ALL subtypes, particularly those with BCL-2 overexpression
.
Targeted therapies are also making headway in the treatment of pediatric ALL, with a focus on minimizing the intensity of treatment and improving outcomes for young patients:
Dasatinib in combination with chemotherapy: Dasatinib, a tyrosine kinase inhibitor, has shown potential when used in combination with chemotherapy for pediatric ALL, particularly in cases with specific genetic alterations. This approach aims to improve the efficacy of treatment while reducing the toxicity experienced by young patients.
Targeted therapies have ushered in a new era of hope for patients with ALL. These treatments offer the potential for better outcomes with fewer side effects compared to traditional therapies. As research advances and more targeted therapies become available, the landscape of ALL treatment will continue to evolve, ultimately improving the quality of life for those living with this challenging disease.
Our Offices
US
16192 Coastal Highway, Lewes, United States of America.
SG
Vision Exchange, # 13-30, No-02 Venture Drive, Singapore-608526
KSA
3738 King Abdullah Branch Rd, 6258 Al Muhammadiyah Dist, 12362, Riyadh, Saudi Arabia
UAE
3401, 34th Floor, Saeed Tower 2, Sheikh Zayed Road, PO Box No. 114429. Dubai, UAE
UK
Level 1, Devonshire House, 1 Mayfair Place, Mayfair W1J 8AJ United Kingdom
IN
2nd Floor, Omaxe Square, Jasola, Behind Apollo Hospital, New Delhi, Delhi 110025
BD
Apt-4A, Level-5, House-407, Road-29, DOHS Mohakhali, Dhaka-1206
TR
Regus - Atasehir Palladium Office Barbaros, Palladium Office and Residence Building, Halk Cd. No:8/A Floor 2 & 3, 34746 Ataşehir/İstanbul
TH
Axcel Health Co. Ltd., UnionSpace Building, 30 Soi Sukhumvit 61, Khlongton-nua, Wattana, Bangkok 10110. Thailand.
NG
Dr Hassan’s Hospital, 5 Katsina Ala street, Maitama- Abuja Nigeria
ET
Hayahulet Golagol Tower, Office Number 1014, 10th Floor
EG
Building 145, Sahl Hamza, Alfaisal Street, Giza - Cairo Egypt
2024, Healthtrip.ae All rights reserved.
Total Hip Replacemen
Upto 80% off
90% Rated
Satisfactory
Total Hip Replacemen
Upto 80% off
90% Rated
Satisfactory
Total Hip Replacemen
Upto 80% off
90% Rated
Satisfactory
ASD Closure
Upto 80% off
90% Rated
Satisfactory
Liver Transplant Sur
Upto 80% off
90% Rated
Satisfactory
85K+
Patients
Served
38+
Countries
Reached
1510+
Hospitals
Partners